Kornimate/medical-research-clean huggingface dataset:
prospective multicentre study on symptoms in first-onset bronchial asthma in children and adolescents

Conditions: Asthma; Asthma in Children; Dyspnea; Cough; Pneumonia; Wheezing; Shortness of Breath; Chest Tightness; Lower Respiratory Tract and Lung Infections; Recurrent Respiratory Tract Infections; Mucus; Plug

Summary: bronchial asthma may present with symptoms other than the commonly reported complaints (cough, chest tightness, shortness of breath and wheezing). less common symptoms include chronic or recurrent productive cough, inspiratory dyspnoea or recurrent pneumonia. children presenting with these symptoms are often diagnosed with asthma bronchiale and benefit from antiasthmatic management.

international guidelines for the diagnosis of bronchial asthma list cough, chest tightness, shortness of breath and wheezing as the four basic symptoms of asthma. the diagnosis of bronchial asthma is based on the presence of two or more of these symptoms over time, together with evidence of bronchial hyperresponsiveness and a favourable response to antiasthmatic treatment. in children under 5 years of age, the occurrence of an isolated cough as a possible asthma symptom (cough variant asthma) is also accepted if bronchial hyperresponsiveness is documented and the difficulty subsides on therapy. pulmonologists also refer children over 5 years of age who have only an isolated cough with no other symptoms before diagnosis. in practice, however, it is also possible to see children whose asthma initially manifests as conditions assessed as recurrent pneumonia, isolated chronic cough of a moist nature or as inspiratory dyspnoea. these atypical symptoms are not oficially counted as asthma symptoms. in this study, the investigators focus on prevalence of typical and atypical asthma symtpoms. furthermore, the investigators study sensitivity of offical asthma symptom questinaire isaac in children with typical and atypical asthma symptoms.

Eligibility criteria:
inclusion criteria: - child 3 - 18 years old, first evaluation in pulmonary outpatient clinic for any of the following respiratory symptoms: cough, shortness of breath, chest tightness, wheezing, recurrent lower respiratory tract and lung infections, dyspnoea of any type, pathological listening findings. exclusion criteria: * other documented chronic respiratory, cardiovascular, neurological, genetic, infectious, metabolic disease, significant immaturity or other disease that may be accompanied by respiratory symptoms.
epidemiological and clinical characteristics of hospitalized patients under 5 years old with rsv infection in central china, wuhan

Conditions: RSV Infection

Summary: the study will be a multicenter, hospital-based retrospective study. we plan to collect the clinical and laboratory data among all hospitalized arti cases in three hospitals in wuhan from june 1, 2020 to may 31, 2023 and then analyze the epidemiological and clinical characteristics of rsv infection, clarify the gene types of epidemics under 5 years old children after the outbreak in wuhan, china.


Eligibility criteria:
inclusion criteria: ①admission age \<5 years old ②clinical diagnosis of acute respiratory tract infections exclusion criteria: hospital acquired arti
study of tadalafil once-a-day for 12 weeks in japanese men with benign prostatic hyperplasia followed by an open-label extension

Conditions: Benign Prostatic Hyperplasia

Summary: this study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the long-term safety and efficacy of tadalafil in japanese men with signs and symptoms of benign prostatic hyperplasia.


Eligibility criteria:
inclusion criteria: * japanese males, 45 years old or older, with benign prostatic hyperplasia (bph) for at least 6 months prior to visit 1 and an international prostate symptom score (ipss) greater than or equal to 13 at visit 2. * agree not to use any other approved or experimental pharmacologic bph, erectile dysfunction (ed), and/or overactive bladder (oab) treatments at any time during the study. * have not taken finasteride or dutasteride therapy, anti-androgenic hormone or any other bph therapy, ed or oab therapy for specified duration of time prior to visit 2. exclusion criteria: * prostate specific antigen (psa) score beyond acceptable range defined for study at visit 1. * history of urinary retention or lower urinary tract (bladder) stones within 6 months of visit 1. * history of urethral obstruction due to stricture, valves, sclerosis, or tumor at visit 1. * clinical evidence of prostate cancer at visit 1. * clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at visit 1. * history of cardiac conditions, including angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study. * history of significant central nervous system (cns) injuries (including stroke or spinal cord injury) within 6 months of visit 1. * use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone (lhrh) agonists/antagonists, or anabolic steroids at visit 1.
collection of tissue samples from patients with stage iii or stage iv ovarian epithelial cancer

Conditions: Ovarian Cancer

Summary: rationale: collecting and storing samples of tumor tissue and ascites fluid from patients to test in the laboratory may help the study of cancer. purpose: this pre-clinical research study is collecting tissue samples and ascites fluid from patients with stage iii or stage iv ovarian/primary peritoneal/fallopian tube epithelial cancer.

objectives: * to generate a translational ovarian cancer model using tumor tissue and cells from patients with stage iii-iv ovarian/primary peritoneal/fallopian tube epithelial cancer for drug response and development. outline: tissue and fluid samples are collected at the time of surgery or paracentesis and used in laboratory experiments and in animal models. health data is collected from patient medical records before, during, and after surgery. after surgery, patients are followed up for 5 years.

Eligibility criteria:
inclusion: • females age 18-80 with a diagnosis of stage iii-iv ovarian cancer, primary fallopian tube, or primary peritoneal papillary serous carcinoma and scheduled treatment for epithelial ovarian malignancies. exclusion: * patients with less than stage iii epithelial ovarian cancer, primary fallopian tube, or primary peritoneal papillary serous carcinoma * patients who have received prior chemotherapy * patients who have nonepithelial ovarian cancer, primary fallopian tube, or primary peritoneal carcinoma * patients who have malignancy other than ovarian cancer, primary fallopian tube, or primary peritoneal carcinoma

Keywords: stage iii ovarian epithelial cancer stage iv ovarian epithelial cancer
effects of carvedilol on cocaine use in humans - 11

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to examine carvedilol effects in response to cocaine.

the purpose of this study was to determine whether carvedilol, and alpha and beta adrenergic blocker, would inhibit the priming effect of cocaine in a laboratory model. a total of 12 subjects were enrolled in this double blind, placebo controlled, outpatient study. after an adaptation session, three experimental sessions were held, 2-9 days apart. on each of 3 experimental sessions, a single oral dose of low (25mg) or high dose of carvedilol (50mg) or placebo were administered. two hours following carvedilol or placebo treatment, subjects received a priming dose of smoked cocaine, 0.4 mg/kg. during the second part of the session, subjects had the option to earn up to 2 tokens by working on a computer task that could later be exchanged for money or deliveries of cocaine. we proposed that blockage of adrenergic receptors by carvedilol would significantly alter the subjective and physiological effects of cocaine.

Eligibility criteria:
inclusion criteria: male/female between 20 and 55. history of smoked or intravenous cocaine use on the average of at least once a week over a 6 month period. current history of good health and normal ekg. not pregnant as determined by pregnancy screening nor breast feeding, using acceptable birth control methods (e.g. birth control pills diaphragm, condoms plus foam) exclusion criteria: current problems with major psychiatric illnesses including bipolar disorder, schizophrenia, or anxiety disorders. history of major medical illnesses including asthma and chronic obstructive pulmonary disease. currently on a drug related parole or probation. treated for chemical dependency withing the past 6 months.
ginger capsules for the chronic treatment of obesity

Conditions: Obesity

Summary: regarding its complex pathogenesis and clinic-epidemiological meaning, different strategies are needed for the treatment of obesity. ginger is the rhizome of a plant with thermogenic and anti-inflammatory effects, and may be a promising alternative as add-on strategy in the treatment for obesity. the primary objective of the current study is to assess whether consumption of ginger as an add-on strategy to restrictive diet is effective to reduce fat body percentage, increase basal metabolic rate and improve loss weight. the secondary objectives are: * to assess the effect of nutritional intervention in quality of diet and weight loss. * to evaluate the effect of ginger on behavioral symptoms and peripheral biomarkers in overweight subjects.

overweight individuals will be interviewed at baseline and after 30, 60, 90, 120, 150 and 180 days from baseline. the following measures will be assessed: body composition (fat body% and free fat body%), anthropometric measures (height, weight, body mass index, waist circumference and abdominal circumference), blood pressure, basal metabolic rate, behavioral symptoms, binge eating (binge eating scale) and peripheral biomarkers. behavioral symptoms will be assessed using the following self-reported questionnaires: beck depression inventory (depression symptoms), beck anxiety inventory (anxiety symptoms), medical outcomes study 36 - item short - form health survey (quality of life) and perceived stress scale (stress). enrolled participants will receive restrictive diet calculated on individual requirements aiming at the loss from two to four kilogram per month in addition to capsules of ginger or placebo, as follows: * group 1 will receive vials containing 90 capsules of 200mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months in addition to restrictive diet. * group 2 will receive vials containing 90 capsules of 200mg of placebo (cellulose) to be taken three times a day for six months in addition to restrictive diet.

Eligibility criteria:
inclusion criteria: * women aged 18-60 years old; * body mass index 25-35 kg/m². exclusion criteria: * pregnant or lactating women; * abuse of alcohol or drugs; * hypersensitivity to ginger; * other endocrine disease; * women in use of insulin or anti-inflammatory and antidepressants drugs.

Keywords: ginger obesity ginger inflammation treatment of obesity
botox® in the treatment of upper facial lines in japan

Conditions: Upper Facial Rhytides; Crow's Feet Lines; Glabellar Lines; Frown Lines

Summary: this study will evaluate the safety and efficacy of botox® (botulinum toxin type a) for the treatment of upper facial lines (crow's feet lines and frown lines).


Eligibility criteria:
inclusion criteria: -moderate to severe crow's feet lines and frown lines exclusion criteria: * current or previous botulinum toxin treatment of any serotype * diagnosis of myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis * facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial peels, or topical retinoid therapy or hormone cream within 3 months * laser treatment or phototherapy of the face for medical purposes, blepharoplasty, brow-lift or related procedure, periorbital permanent make-up, or oral retinoid therapy within one year * medium-depth or deep facial peels within 5 years * prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, periorbital treatment with fillers, implantation or transplantation)
diffusion mri-1 imaging database

Conditions: Epilepsy; Tumor; Healthy; Other

Summary: the purpose of the dmri-1 data collection study is to establish a database of clinical images and limited medical history information from patients that have previously received a dmri scan. all data collected will be de-identified. no safety or effectiveness assessments will be completed.


Eligibility criteria:
inclusion criteria: 1. patient is either ≥ 18 years and has previously received an acceptable dmri scan(s) with at least 30 unique gradient directions or \< 18 years who has previously received an acceptable dmri scan of any number of unique gradient directions and who is allowed to participate in this type of research project (e.g., irb/ec approval with waiver of consent) per irb/ec 2. acceptable dmri scan was completed prior to site activation in the study exclusion criteria: none
cardiovascular impact, quality e quantity of sleep in bed partners of patients with obstructive sleep apnea

Conditions: Sleep Apnea Syndromes

Summary: obstructive sleep apnea (osa) is a common clinical condition associate with a negative impact not limited to the patients but also to the partner that sleep in the same bed. is it reasonable to speculate that the partner suffer sleep deprivation, increased level of irritability, insomnia, fatigue, among others due to the loud snoring caused by the osa patient. although previous data reported impaired sleep quality in partners of patients with osa, it is not clear in literature whether osa promotes cardiovascular impact and if the treatment of osa promotes some cardiovascular benefits in (the) partner beyond the improvements in the subjective and objective sleep. thus, the main objectives of this randomized controlled study are: to evaluate the impact of three months of randomization (treatment with nasal cpap or nasal strips) on the endothelial function, blood pressure (ambulatory blood pressure monitoring), sleep duration (wrist actigraphy for 1 week) and sleep quality (pittsburgh questionnaire) and the frequency of osa in the bed partners of patients with moderate to severe osa.


Eligibility criteria:
inclusion criteria: * bed partners of patients with moderate to severe osa exclusion criteria: * bed partners with osa using specific treatment.
open-label duloxetine extension phase in patients who have completed previous duloxetine trials

Conditions: Major Depressive Disorder

Summary: a study in patients with depression


Eligibility criteria:
inclusion criteria: * male or female patients at least 18 years of age who have previously completed satisfactorily the lilly sponsored previous clinical trial, and who are clinically controlled with duloxetine, as judge by the investigator * all females must test negative for a urine pregnancy test at visit 1. females of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopausal) must agree to utilize medically acceptable and reliable means of birth control as determined by the investigator during the study. women who are pregnant or breast-feeding may not participate in the study. * must sign the informed consent document (icd). exclusion criteria: * have received treatment within the last 30 days with a drug ( not including study drug) that has not received regulatory approval for any indication at the time of study entry. * patients who have entered the optional tapering period of the previous study. * in the opinion of the investigator, patients judged to be at serious suicidal risk. * treatment with a maoi within 14 days prior to visit 1 or potential need to use maoi during the study or within 5 days of discontinuation of the study drug. * any patient who previously experienced a serious adverse event while taking duloxetine unless approved by the lilly physician
clinical study of raloxifene and strontium ranelate in postmenopausal osteoporosis

Conditions: Postmenopausal Osteoporosis; Compliance

Summary: the purpose of this study was to compare compliance and efficacy of raloxifene and strontium ranelate in a group of women with postmenopausal osteoporosis.

objective: to compare the performance of raloxifene and strontium rannelate in the management of women with postmenopausal osteoporosis. design: prospective, open label study. setting: university hospital menopause unit. patients: 80 women with postmenopausal osteoporosis were assigned to either raloxifene (60 mg/d) or strontium ranelate (2g/d). participants were followed for 1 year. main outcome measure(s): compliance with each regime. secondary objectives were parameters of efficacy, including changes in bone mineral density and bone biochemical markers.

Eligibility criteria:
inclusion criteria: * postmenopausal women with densitometric osteoporosis exclusion criteria: * secondary osteoporosis

Keywords: postmenopausal osteoporosis compliance bone mineral density bonemarkers
success of zirconia and stainless steel crowns for permanent molars

Conditions: Caries Active; Dentin, Carious

Summary: the purpose of this study is to evaluate and compare the clinical and radiographic performance of zirconia and stainless steel crowns on permanent molar

zirconia and stainless steel crowns will be placed on at least two permanent molars, in a split mouth design. 100 patients will be included in the study. the teeth will be randomized into two groups according to the crown type. group 1: zirconia crown 2: stainless steel crown. plaque index, gingival index, crown retention, presence of restoration failure, gingival margin extension and pulpal health of the teeth will be clinically evaluated at baseline and 1., 6., 12., 18., 24. months. the restorations will be evaluated radiographically at 6., 12. and 18. months. intra-oral photos will be taken directly after treatment and at control appointments. the data will be analysed statistically using fisher's exact test and pearson's chi-square test; and log-rank and the kaplan-meier will be used to estimate survival percentages.

Eligibility criteria:
inclusion criteria: * patients and parent of the patients who accept to participate and sign the informed consent * patients who have at least two permanent molars with caries that require crown restoration * patients that have good cooperation to the procedure exclusion criteria: * patients and parent of the patients who don't accept to participate and sign the informed consent * teeth that doesn't have opposing permanent molars * patients who have bruxism or deep-bite * patient who are allergic to nickel

Keywords: zirconia crowns stainless steel crowns dental caries
targeted cognitive training in clinical high risk (chr) for psychosis

Conditions: Clinical High Risk for Psychosis

Summary: this project is a randomized-controlled trial to test the efficacy of computer-based targeted cognitive training (tct) versus a placebo intervention of commercial computer games in adolescent/young adults at clinical high risk (chr) for psychosis. tct is designed to optimize learning-induced neuroplasticity in vulnerable neurocognitive systems. a main aim is to test the hypothesis that this neuroscience-guided tct intervention will improve neural function, and that these neural improvements will improve cognition and functional outcome. chr participants will be randomly assigned to 40 hours of tct or placebo computer games completed within 10 weeks. tct consists of 20 hours of training in cognition, including processing speed, memory, attention, and cognitive control followed by 20 hours of training in social cognition including affect recognition and theory of mind. neuroimaging, cognition, social cognition, clinical symptoms, and functional status will be assessed at baseline, after 20 hours/5 weeks of cognitive training (mid-intervention), and after 20 hours/5 weeks of social-cognitive training (post-intervention). cognition, social cognition, symptoms, and functioning will also be assessed at a 9 month follow-up (i.e. 9 months after intervention completion). we predict that tct will lead to improvements in neurocognitive function and functional status. the results of this study will provide important information about a benign, non-pharmacological intervention for improving cognition and functional outcome in chr individuals.


Eligibility criteria:
inclusion criteria: * english speaking * one or more psychosis-risk syndromes as defined by the structured interview for psychosis-risk syndromes (sips) exclusion criteria: * intelligence quotient (iq) \< 70 * major medical illness or neurological disorder * lifetime history of axis i psychotic disorder and/or clear evidence that psychosis-risk syndrome is due to non-schizophrenia-spectrum axis i or axis ii disorder

Keywords: schizophrenia psychosis at risk prodrome attenuated psychosis syndrome
study of the cardiometabolic effects of obesity pharmacotherapy

Conditions: Obesity; Blood Pressure

Summary: the aim of the present study is to compare the efficacy of liraglutide vs. naltrexone/bupropion on metabolic and cardiovascular risk markers, weight loss, as well as the postprandial secretion of gastrointestinal hormones involved in hunger and satiety, after a test meal. the study will include 40 patients, who will further be divided into two treatment groups (20 patients on liraglutide vs. 20 patients on naltrexone/bupropion). the patients will be examined at baseline, 3 and 6 months after the treatment initiation.

this is a prospective study of patients aged ≥18 years, who are overweight (bmi ≥ 27 kg / m2 in the presence of dyslipidemia or hypertension or obstructive sleep apnea or fatty infiltration or prediabetes) or obese patients (bmi ≥ 30 kg / m2). patients' data will be collected before starting medication (time 0) and at 3 and 6 months under treatment in the clinical practice of the selected drug, as described in the drug's package leaflet, along with a simultaneous dietary intervention and exercise. patient groups will be comparable in age, gender and bmi. the aim of the study is the comparison of the efficacy of liraglutide vs. naltrexone/bupropion in metabolic and cardiovascular markers. the following parameters will be measured: * weight, height, waist and hip circumference * 24-hour recording of blood pressure and heart rate * hba1c, total cholesterol, ldl, hdl, urine albumin/creatinine ratio * bioelectric impedance for determination of total and visceral fat and muscle mass indirect calorimetry for the determination of resting metabolic rate and total energy expenditure * determination of baroreflex sensitivity (brs) and heart rate variability (hrv) to investigate the function of the autonomic nervous system * blood sample test meal at 0, 30, 60, 90, 120, 150 and 180 min to determine insulin concentration and gastrointestinal hormones involved in hunger and satiety with modern indirect calorimetry to determine postprandial thermogenic analog scales (vas) * neuropathy tests * assessment of quality of life with the sf-36 questionnaire and assessment of the feeling of hunger and satiety * echocardiographic determination of the left systolic and telodiastolic diameter of the left ventricle, cardiac fat and the tei index at times 0 and 6 months with medication * pericardial fat

Eligibility criteria:
inclusion criteria: * age ≥18 years with bmi ≥ 30 kg / m2 or bmi ≥ 27 kg / m2 in the presence of dyslipidemia or hypertension or obstructive sleep apnea or fatty infiltration or prediabetes. exclusion criteria: 1. presence of any clinical contraindications for the administration of liraglutide or bupropion / naltrexone 2. bariatric surgery 3. diabetes type 2 4. active malignancy 5. medication that affects weight (eg corticosteroids, phenothiazines)